References: Prevention of decompensation in patients with compensated cirrhosis

  • de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-74. https://www.ncbi.nlm.nih.gov/pubmed/35120736
  • European Association for the Study of the Liver Clinical Practice Guideline Panel. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75(3):659-89. https://www.ncbi.nlm.nih.gov/pubmed/34166721
  • Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis. Clin Gastroenterol Hepatol 2022. https://www.ncbi.nlm.nih.gov/pubmed/35842118
  • McDowell HR, Chuah CS, Tripathi D, Stanley AJ, Forrest EH, Hayes PC. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study. Aliment Pharmacol Ther 2021;53(4):531-9. https://www.ncbi.nlm.nih.gov/pubmed/33296526
  • Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, et al. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. Am J Gastroenterol 2021;116(4):723-32. https://www.ncbi.nlm.nih.gov/pubmed/33982942
  • Villanueva C, Albillos A, Genesca J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393(10181):1597-608. https://www.ncbi.nlm.nih.gov/pubmed/30910320
  • Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol 2022. https://www.ncbi.nlm.nih.gov/pubmed/35661713
  • Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, et al. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Saf 2018;41(6):603-13. https://www.ncbi.nlm.nih.gov/pubmed/29330714